how to manage the IVF during COVID-19 pandemic among diabetic females: a scientific perspective

Bibliographic Information
Authors: Bukhari M.A.; Al Edrisy S.A.; Sibai S.S.; El-Malky A.M.
Journal: Clinical Diabetology
Publisher: Via Medica
Publication Date: 2021
Volume / Issue: Volume 9 / Issue 6
Pages: 372–377
ISSN: 24507458
Scopus: View on Scopus
Document Type: Article
Authors and Affiliations
Bukhari M.A., King Khalid University Hospital, College of Medicine, Riyadh, Saudi Arabia; Al Edrisy S.A., King Khalid University Hospital, College of Medicine, Riyadh, Saudi Arabia; Sibai S.S., King Khalid University Hospital, College of Medicine, Riyadh, Saudi Arabia; El-Malky A.M., King Khalid University Hospital, College of Medicine, Riyadh, Saudi Arabia, Public Health and Community Medicine Department, Theodor Bilharz Research Institute, Academy of Scientific Research, Ministry of Higher Education, Cairo, Egypt
Abstract
Diabetes is a challenging clinical problem facing obstetricians and gynecologists when it comes to in vitro fertilization and embryo transfer (IVF-ET). During the COVID-19 pandemic we are living nowadays, COVID-19 becomes a new superimposing challenge for diabetic females need IVF-ET procedures. The persistent lock-down of diabetic health facilities already advised by numerous organizations and contributing to challenging diabetes treatment is harmful to the whole population and in particular to patients with infertilities. Around 0.3% of all babies born last year were conceived with IVF-ET therapies worldwide. We recommend remedies to foresee more delicate infertility cases so as to prepare for a resumption of temporarily suspended fertility treatment.. In an age of crucial challenges for our national health services, complication prevention and tension management can help competent agencies and health providers identify patients that should be preferred to begin fertility treatment in a healthy environment. What we consider as a possible possibility is the gradual restart of IVF, which needs many measures for diabetic patients. The problem of restarting IVF installations after the current lockdown is real since each nation follows a certain recovery curve. Especially as a result of silent dissemination, attention should be provided to COVID-19 infection among patients and health-care staff after the restart of IVF therapy. (Clin Diabetol 2020; 9; 6: 372–377) © 2020 Via Medica. All rights reserved.
Keywords
COVID-19; Diabetic; Females; IVF; Pandemic; antidiabetic agent; chloroquine; glucocorticoid; hydroxychloroquine; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; lopinavir; ritonavir; sulfonylurea; Article; coronavirus disease 2019; diabetes mellitus; diabetic patient; early menopause; embryo transfer; female; female fertility; fertility clinic; glycemic control; human; in vitro fertilization; infertility therapy; lockdown; national health service; ovary hyperstimulation; ovary polycystic disease; pregnancy; pregnancy diabetes mellitus; health care facility; outcome assessment
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
